<DOC>
	<DOC>NCT02694978</DOC>
	<brief_summary>To evaluate the safety of 1.020 g of IV ferumoxytol compared to 1.500 g of IV Ferric Carboxymaltose (FCM).</brief_summary>
	<brief_title>A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)</brief_title>
	<detailed_description>To assess the incidence of moderate to severe hypersensitivity reactions, including anaphylaxis, and of moderate to severe hypotension.</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Subjects with IDA and in whom intravenous iron treatment is indicated and defined as: Subjects with documented hemoglobin &lt;12.0 g/dL for females and &lt;14.0 g/dL for males within 60 days of dosing And Subjects with documented TSAT ≤20% or Ferritin ≤100 ng/mL within 60 days of dosing Documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate (as per oral iron history questionnaire) Subject is capable of understanding and complying with the protocol requirements and available for the duration of the study All subjects (male and female) of childbearing potential who are sexually active who agree to routinely use adequate contraception from randomization throughout the duration of the study Known hypersensitivity reaction to any component of ferumoxytol or FCM History of allergy to an IV iron History of multiple drug allergies Subjects with dialysis dependent CKD Hemoglobin ≤7.0 g/dL Female subjects who are pregnant, intend to become pregnant, are breastfeeding, have a positive serum/urine pregnancy test or not willing to use effective contraceptive precautions during the study (including females of childbearing potential who are partners of male subjects)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>iron deficiency anemia</keyword>
	<keyword>IDA</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>ferric carboxymaltose</keyword>
	<keyword>FCM</keyword>
	<keyword>Injectafer</keyword>
</DOC>